<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635814</url>
  </required_header>
  <id_info>
    <org_study_id>YD312-01-P2</org_study_id>
    <nct_id>NCT03635814</nct_id>
  </id_info>
  <brief_title>The Study to YD312 Tablet in Patients With Diabetic Macular Edema</brief_title>
  <official_title>Multi-center, Randomized, Double-blind, Dose-finding, Phase 2a Clinical Trial to Evaluate the Effecacy and Safety of YD312 Tablet in Patients With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>YD Global Life Science Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>YD Global Life Science Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study objectives is to evaluate the efficacy of YD312 to improve visual acuity in&#xD;
      patients with diabetic macular edema (DME) compared to placebo and determine optimal dose of&#xD;
      phase 2b study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      These study results present the possibility that imatinib can be used as a new DME inhibiting&#xD;
      agent by involving VEGF-independent ocular angiogenesis, not action points of existing&#xD;
      agents, in effectively inhibiting excessive vascular angiogenesis observed in oxygen-induced&#xD;
      retinopathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">July 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects who finally meet inclusion/exclusion criteria will be randomized into lower dose group (YD312 Tablet 50 mg), middle dose group (YD312 Tablet 150 mg), higher dose group (YD312 Tablet 350 mg), and placebo group as a ratio of 1:1:1:1 and the relevant investigational product will be administered for 12 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ETDRS BCVA latter score from baseline at Week 12 ( ETDRS chart reading at least 3 letters)</measure>
    <time_frame>BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ETDRS BCVA latter score from baseline at Weeks 4 and 8</measure>
    <time_frame>BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement or worsening rate of ETDRS BCVA from baseline at Weeks 4, 8, and 12</measure>
    <time_frame>BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12)</time_frame>
    <description>Proportion of improved subjects: ≥ 1 letter score increase, ≥ 10 letter score increase, ≥ 15 letter score increase&#xD;
Proportion of worsened subjects: ≥ 5 letter score decrease, ≥ 10 letter score decrease, ≥ 15 letter score decrease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CST from baseline at Weeks 4, 8, and 12</measure>
    <time_frame>BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Macular Edema(DME)</condition>
  <arm_group>
    <arm_group_label>YD312 drug treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YD312 placebo drug treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YD312 50mg</intervention_name>
    <description>YD312 50mg * 1 + placebo 6 tablets</description>
    <arm_group_label>YD312 drug treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YD312 150mg</intervention_name>
    <description>YD312 50mg * 3 + placebo 6 tablets</description>
    <arm_group_label>YD312 drug treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YD312 350mg</intervention_name>
    <description>YD312 50mg * 7 tablets</description>
    <arm_group_label>YD312 drug treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>YD312 0mg * 7 tabets</description>
    <arm_group_label>YD312 placebo drug treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Screening Inclusion Criteria&#xD;
&#xD;
             Study subjects must be eligible for the following criteria at screening:&#xD;
&#xD;
               1. Subject who is male or female ≥ 19 years of age&#xD;
&#xD;
               2. Subject who has a diagnosis of Type 1 or 2 diabetes&#xD;
&#xD;
               3. Subject who has study eye with definite retinal thickening due to diabetic&#xD;
                  macular edema involving the center of the macula&#xD;
&#xD;
               4. Subject who has voluntarily signed an informed consent form&#xD;
&#xD;
          2. Randomization Inclusion Criteria&#xD;
&#xD;
        Study eye must be eligible for the following criteria at randomization:&#xD;
&#xD;
          1. Subject who has study eye with central subfield thickness (CST) of ≥ 300 μm on optical&#xD;
             coherence tomography (OCT)&#xD;
&#xD;
          2. Subject who has study eye with an early treatment diabetic retinopathy study (ETDRS)&#xD;
             best-corrected visual acuity (BCVA) letter score ranging from 39 to 78, inclusive&#xD;
             (approximate Snellen equivalent of 20/32 - 20/160)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject who has study eye with any of the following criteria:&#xD;
&#xD;
               1. Subject whose primary cause of macular edema is non-diabetic disease/condition&#xD;
                  (e.g., cataract extraction, vitreomacular interface abnormalities)&#xD;
&#xD;
               2. Subject who is expected to have no improvement of decreased visual acuity in the&#xD;
                  opinion of investigator, even if macular edema is resolved (e.g., foveal atrophy,&#xD;
                  abnormal pigmentation, dense subfoveal hard exudate)&#xD;
&#xD;
               3. Subject who has proliferative diabetic retinopathy.&#xD;
&#xD;
               4. Subject who took the following within 3 months before randomization&#xD;
&#xD;
                  ① Focal/grid laser photocoagulation&#xD;
&#xD;
                  ② Intravitreal/circumbulbar corticosteroid, anti-VEGF and pro-VEGF (but, no&#xD;
                  wash-out period is required for the corticosteroid eyedrops)&#xD;
&#xD;
               5. Subject who took panretinal photocoagulation (PRP) or intravitreal dexamethasone&#xD;
                  implant within 6 months before randomization&#xD;
&#xD;
               6. Subject who has a history of vitrectomy&#xD;
&#xD;
               7. Subject who took major ophthalmic surgeries (all intraocular surgeries including&#xD;
                  cataract extraction and scleral buckle) within 6 months before randomization&#xD;
&#xD;
          2. Subject who had systemic treatment of corticosteroid or anti-VEGF within 3 months&#xD;
             before randomization.&#xD;
&#xD;
          3. Subject who administered vaccinium myrtillus extract or dobesilate calcium within 2&#xD;
             weeks before randomization&#xD;
&#xD;
          4. Subject who is suspected to require administration/treatment of drug/procedure that&#xD;
             may affect the efficacy evaluation before the participation of clinical trial or&#xD;
             during clinical trial (refer to '10.4 Combination Therapy and Contraindication').&#xD;
&#xD;
          5. Subject who has the following illness or abnormal laboratory test values:&#xD;
&#xD;
               1. Subject who has a hypersensitivity to any excipients of the investigational&#xD;
                  product or similar class of drug and ingredient&#xD;
&#xD;
               2. Subject who has uncontrolled hypertension (SBP &gt; 160 mmHg or DBP &gt;100 mmHg)&#xD;
&#xD;
               3. Subject who has uncontrolled diabetes (HbA1c &gt; 10.0%)&#xD;
&#xD;
               4. Subject who has uncontrolled glaucoma in either eye (intraocular pressure (IOP) &gt;&#xD;
                  24 mmHg on medication or according to the investigator's judgment)&#xD;
&#xD;
               5. ANC &lt; 1.5 × 109/L&#xD;
&#xD;
               6. Platelet &lt; 125 × 109/L&#xD;
&#xD;
               7. Total bilirubin &gt; 1.5 × ULN&#xD;
&#xD;
               8. AST or ALT &gt; 2 × ULN&#xD;
&#xD;
               9. Clcr* &lt; 40 mL/min&#xD;
&#xD;
                  * Clcr (Cockcroft-Gault formula)&#xD;
&#xD;
                  = [(140 - age) x weight(kg) (x 0.85 for females)] / [72 x serum creatinine (Scr)&#xD;
                  (mg/dL)]&#xD;
&#xD;
              10. Severe heart failure (NYHA class III/IV)&#xD;
&#xD;
              11. Malignant tumor within 5 years before randomization&#xD;
&#xD;
              12. Subject who is known to be HIV positive, is active hepatitis B patient or&#xD;
                  carrier, or is hepatitis C patient&#xD;
&#xD;
              13. Ocular inflammatory diseases such as uveitis, conjunctivitis, and blepharitis in&#xD;
                  either eye. However, the participation of subject in this study is considered at&#xD;
                  the discretion of investigator.&#xD;
&#xD;
              14. Unstable angina, myocardial infarction, transient ischemic attack, cerebral&#xD;
                  infarction, coronary artery bypass surgery, or transluminal coronary angioplasty&#xD;
                  within 6 months before screening&#xD;
&#xD;
          6. Pregnant woman, lactating woman, or female or male subject of childbearing potential&#xD;
&#xD;
             *hormonal contraceptives, intrauterne contraceptive device, sterilization of spouse&#xD;
             (e.g., vasectomy, tubal ligation), double-barrier method (e.g., combinational use of&#xD;
             spermicides and condoms, diaphragm, contraceptive sponge, of FemCap)&#xD;
&#xD;
          7. Subject who took administraion/procedure of other investigational products or medical&#xD;
             devices within longer period between 30 days before screening or over 5time half-life.&#xD;
&#xD;
          8. Subject, at the discretion of the investigator, who is unsuitable to participate in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AXIS Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Flolida Clinical Trials</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Retina Consultants</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elman Retina Group</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials LV</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitro-Retinal Consultants, Inc</name>
      <address>
        <city>Painesville</city>
        <state>Ohio</state>
        <zip>44077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phensylvania Retina Specialists</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-Clinsearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wagner Macula &amp; Retina Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Chung-gu</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon-si</city>
        <state>Chung-gu</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangmam-gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje National University Busan Park Hospital</name>
      <address>
        <city>Busan</city>
        <state>Jin-gu</state>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Medical Center</name>
      <address>
        <city>Guri-si</city>
        <state>Kyeonggi-do</state>
        <zip>11923</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinicaltrial, DME, DR, AMD, imatinib mesylate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

